Orchestra BioMed develops the BackBeat Cardiac Neuromodulation Therapy™ and Virtue® Sirolimus AngioInfusion™ Balloon to treat hypertension and atherosclerotic artery disease. These investigational technologies aim to reduce blood pressure and deliver sirolimus during balloon angioplasty, addressing significant health risks associated with these conditions.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVFounders
Product
Problem
Hypertension and atherosclerotic artery disease pose significant health risks, yet effective treatments are lacking. Current methods for managing these conditions often involve systemic medications or invasive procedures with potential complications.
Solution
Orchestra BioMed is developing two investigational technologies: BackBeat Cardiac Neuromodulation Therapy (CNT) and Virtue Sirolimus AngioInfusion Balloon (SAB). BackBeat CNT, also known as atrioventricular interval modulation (AVIM) therapy, is a bioelectronic treatment designed to reduce blood pressure by modulating autonomic nervous system responses. Virtue SAB is a drug/device combination product candidate that delivers a proprietary extended-release formulation of sirolimus (SirolimusEFR) during balloon angioplasty, without requiring balloon coating or a permanent implant, for the treatment of atherosclerotic artery disease.
Target Audience
The primary target audience includes patients with hypertension and atherosclerotic artery disease, as well as medical device companies seeking partnership opportunities for innovative therapeutic products.
Features
- BackBeat CNT (AVIM therapy): Patented bioelectronic treatment designed for immediate, substantial, and persistent reduction in blood pressure.
- BackBeat CNT (AVIM therapy): Modulates autonomic nervous system responses to maintain blood pressure reduction.
- Virtue SAB: Drug/device combination product candidate for treating artery disease.
- Virtue SAB: Delivers SirolimusEFR, an extended-release formulation of sirolimus, during balloon angioplasty.
- Virtue SAB: Eliminates the need for balloon coating or a permanent implant.